DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2014-04, Vol.58 (8), p.1072-1083
Hauptverfasser: Roberts, Jason A., Paul, Sanjoy K., Akova, Murat, Bassetti, Matteo, De Waele, Jan J., Dimopoulos, George, Kaukonen, Kirsi-Maija, Koulenti, Despoina, Martin, Claude, Montravers, Philippe, Rello, Jordi, Rhodes, Andrew, Starr, Therese, Wallis, Steven C., Lipman, Jeffrey
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1083
container_issue 8
container_start_page 1072
container_title Clinical infectious diseases
container_volume 58
creator Roberts, Jason A.
Paul, Sanjoy K.
Akova, Murat
Bassetti, Matteo
De Waele, Jan J.
Dimopoulos, George
Kaukonen, Kirsi-Maija
Koulenti, Despoina
Martin, Claude
Montravers, Philippe
Rello, Jordi
Rhodes, Andrew
Starr, Therese
Wallis, Steven C.
Lipman, Jeffrey
description Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T> MIC ) and 100% (100% f T> MIC ) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. Results. We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48–73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14–24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T> MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P=.009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T> MIC ratios (OR, 1.02 and 1.56, respectively; P
doi_str_mv 10.1093/cid/ciu027
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1701481301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>24031748</jstor_id><sourcerecordid>24031748</sourcerecordid><originalsourceid>FETCH-LOGICAL-j196t-51f2233b53dfb67e3a021fec031607df738ea53f5954a1912142c31dd18f38e73</originalsourceid><addsrcrecordid>eNpNkEtOwzAQhi0EoqWwYQ_ykk3AE8dx0g2qUh6VIoEEXVdOYiNXqVNsp1JvwVk4CGfCqIC6GM3j_-bXaBA6B3INJKc3tW5C9CTmB2gIjPIoZTkchpqwLEoymg3QiXNLQgAywo7RIE6SOE8oH6KP6aScjfFUKm20ecMT43WlO69rXMqNbB3WBs-Ml8bpjcSFsBLPjfb4WXgtjXdjPAmjorc2dPjrMypF7cVq32jaOenwS6-Urn92sOosLqwOmmjbLZ617b_d7Sk6UqJ18uw3j9D8_u61eIzKp4dZMSmjJeSpjxioOKa0YrRRVcolFSQGJWtCISW8UZxmUjCqWM4SATnEkMQ1haaBTAWJ0xG62vmubffeS-cXK-1q2bbCyK53C-AEkgwogYBe_qJ9tZLNYm31Stjt4u-LAbjYAUvnO7unh2t4-P83-VB-HQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1701481301</pqid></control><display><type>article</type><title>DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Roberts, Jason A. ; Paul, Sanjoy K. ; Akova, Murat ; Bassetti, Matteo ; De Waele, Jan J. ; Dimopoulos, George ; Kaukonen, Kirsi-Maija ; Koulenti, Despoina ; Martin, Claude ; Montravers, Philippe ; Rello, Jordi ; Rhodes, Andrew ; Starr, Therese ; Wallis, Steven C. ; Lipman, Jeffrey</creator><creatorcontrib>Roberts, Jason A. ; Paul, Sanjoy K. ; Akova, Murat ; Bassetti, Matteo ; De Waele, Jan J. ; Dimopoulos, George ; Kaukonen, Kirsi-Maija ; Koulenti, Despoina ; Martin, Claude ; Montravers, Philippe ; Rello, Jordi ; Rhodes, Andrew ; Starr, Therese ; Wallis, Steven C. ; Lipman, Jeffrey ; DALI Studya ; DALI Study</creatorcontrib><description>Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T&gt; MIC ) and 100% (100% f T&gt; MIC ) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. Results. We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48–73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14–24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T&gt; MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P=.009). Positive clinical outcome was associated with increasing 50% f T&gt;MIC and 100% f T&gt; MIC ratios (OR, 1.02 and 1.56, respectively; P&lt;.03), with significant interaction with sickness severity status. Conclusions. Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciu027</identifier><identifier>PMID: 24429437</identifier><language>eng</language><publisher>United States: OXFORD UNIVERSITY PRESS</publisher><subject>Aged ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - pharmacokinetics ; Antibiotics ; ARTICLES AND COMMENTARIES ; Bacterial Infections - drug therapy ; beta-Lactams - administration &amp; dosage ; beta-Lactams - pharmacokinetics ; Blood Chemical Analysis ; Critical care ; Critical Illness ; Female ; Health care industry ; Health outcomes ; Hospitals ; Humans ; Infections ; Intensive Care Units ; International Cooperation ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Models, Statistical ; Pathogens ; Pharmacokinetics ; Prospective Studies ; Treatment Outcome ; University hospitals</subject><ispartof>Clinical infectious diseases, 2014-04, Vol.58 (8), p.1072-1083</ispartof><rights>Copyright © 2014 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/24031748$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/24031748$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24429437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roberts, Jason A.</creatorcontrib><creatorcontrib>Paul, Sanjoy K.</creatorcontrib><creatorcontrib>Akova, Murat</creatorcontrib><creatorcontrib>Bassetti, Matteo</creatorcontrib><creatorcontrib>De Waele, Jan J.</creatorcontrib><creatorcontrib>Dimopoulos, George</creatorcontrib><creatorcontrib>Kaukonen, Kirsi-Maija</creatorcontrib><creatorcontrib>Koulenti, Despoina</creatorcontrib><creatorcontrib>Martin, Claude</creatorcontrib><creatorcontrib>Montravers, Philippe</creatorcontrib><creatorcontrib>Rello, Jordi</creatorcontrib><creatorcontrib>Rhodes, Andrew</creatorcontrib><creatorcontrib>Starr, Therese</creatorcontrib><creatorcontrib>Wallis, Steven C.</creatorcontrib><creatorcontrib>Lipman, Jeffrey</creatorcontrib><creatorcontrib>DALI Studya</creatorcontrib><creatorcontrib>DALI Study</creatorcontrib><title>DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T&gt; MIC ) and 100% (100% f T&gt; MIC ) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. Results. We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48–73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14–24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T&gt; MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P=.009). Positive clinical outcome was associated with increasing 50% f T&gt;MIC and 100% f T&gt; MIC ratios (OR, 1.02 and 1.56, respectively; P&lt;.03), with significant interaction with sickness severity status. Conclusions. Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.</description><subject>Aged</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Antibiotics</subject><subject>ARTICLES AND COMMENTARIES</subject><subject>Bacterial Infections - drug therapy</subject><subject>beta-Lactams - administration &amp; dosage</subject><subject>beta-Lactams - pharmacokinetics</subject><subject>Blood Chemical Analysis</subject><subject>Critical care</subject><subject>Critical Illness</subject><subject>Female</subject><subject>Health care industry</subject><subject>Health outcomes</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infections</subject><subject>Intensive Care Units</subject><subject>International Cooperation</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Pathogens</subject><subject>Pharmacokinetics</subject><subject>Prospective Studies</subject><subject>Treatment Outcome</subject><subject>University hospitals</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkEtOwzAQhi0EoqWwYQ_ykk3AE8dx0g2qUh6VIoEEXVdOYiNXqVNsp1JvwVk4CGfCqIC6GM3j_-bXaBA6B3INJKc3tW5C9CTmB2gIjPIoZTkchpqwLEoymg3QiXNLQgAywo7RIE6SOE8oH6KP6aScjfFUKm20ecMT43WlO69rXMqNbB3WBs-Ml8bpjcSFsBLPjfb4WXgtjXdjPAmjorc2dPjrMypF7cVq32jaOenwS6-Urn92sOosLqwOmmjbLZ617b_d7Sk6UqJ18uw3j9D8_u61eIzKp4dZMSmjJeSpjxioOKa0YrRRVcolFSQGJWtCISW8UZxmUjCqWM4SATnEkMQ1haaBTAWJ0xG62vmubffeS-cXK-1q2bbCyK53C-AEkgwogYBe_qJ9tZLNYm31Stjt4u-LAbjYAUvnO7unh2t4-P83-VB-HQ</recordid><startdate>20140415</startdate><enddate>20140415</enddate><creator>Roberts, Jason A.</creator><creator>Paul, Sanjoy K.</creator><creator>Akova, Murat</creator><creator>Bassetti, Matteo</creator><creator>De Waele, Jan J.</creator><creator>Dimopoulos, George</creator><creator>Kaukonen, Kirsi-Maija</creator><creator>Koulenti, Despoina</creator><creator>Martin, Claude</creator><creator>Montravers, Philippe</creator><creator>Rello, Jordi</creator><creator>Rhodes, Andrew</creator><creator>Starr, Therese</creator><creator>Wallis, Steven C.</creator><creator>Lipman, Jeffrey</creator><general>OXFORD UNIVERSITY PRESS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20140415</creationdate><title>DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?</title><author>Roberts, Jason A. ; Paul, Sanjoy K. ; Akova, Murat ; Bassetti, Matteo ; De Waele, Jan J. ; Dimopoulos, George ; Kaukonen, Kirsi-Maija ; Koulenti, Despoina ; Martin, Claude ; Montravers, Philippe ; Rello, Jordi ; Rhodes, Andrew ; Starr, Therese ; Wallis, Steven C. ; Lipman, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j196t-51f2233b53dfb67e3a021fec031607df738ea53f5954a1912142c31dd18f38e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Antibiotics</topic><topic>ARTICLES AND COMMENTARIES</topic><topic>Bacterial Infections - drug therapy</topic><topic>beta-Lactams - administration &amp; dosage</topic><topic>beta-Lactams - pharmacokinetics</topic><topic>Blood Chemical Analysis</topic><topic>Critical care</topic><topic>Critical Illness</topic><topic>Female</topic><topic>Health care industry</topic><topic>Health outcomes</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infections</topic><topic>Intensive Care Units</topic><topic>International Cooperation</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Pathogens</topic><topic>Pharmacokinetics</topic><topic>Prospective Studies</topic><topic>Treatment Outcome</topic><topic>University hospitals</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roberts, Jason A.</creatorcontrib><creatorcontrib>Paul, Sanjoy K.</creatorcontrib><creatorcontrib>Akova, Murat</creatorcontrib><creatorcontrib>Bassetti, Matteo</creatorcontrib><creatorcontrib>De Waele, Jan J.</creatorcontrib><creatorcontrib>Dimopoulos, George</creatorcontrib><creatorcontrib>Kaukonen, Kirsi-Maija</creatorcontrib><creatorcontrib>Koulenti, Despoina</creatorcontrib><creatorcontrib>Martin, Claude</creatorcontrib><creatorcontrib>Montravers, Philippe</creatorcontrib><creatorcontrib>Rello, Jordi</creatorcontrib><creatorcontrib>Rhodes, Andrew</creatorcontrib><creatorcontrib>Starr, Therese</creatorcontrib><creatorcontrib>Wallis, Steven C.</creatorcontrib><creatorcontrib>Lipman, Jeffrey</creatorcontrib><creatorcontrib>DALI Studya</creatorcontrib><creatorcontrib>DALI Study</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roberts, Jason A.</au><au>Paul, Sanjoy K.</au><au>Akova, Murat</au><au>Bassetti, Matteo</au><au>De Waele, Jan J.</au><au>Dimopoulos, George</au><au>Kaukonen, Kirsi-Maija</au><au>Koulenti, Despoina</au><au>Martin, Claude</au><au>Montravers, Philippe</au><au>Rello, Jordi</au><au>Rhodes, Andrew</au><au>Starr, Therese</au><au>Wallis, Steven C.</au><au>Lipman, Jeffrey</au><aucorp>DALI Studya</aucorp><aucorp>DALI Study</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2014-04-15</date><risdate>2014</risdate><volume>58</volume><issue>8</issue><spage>1072</spage><epage>1083</epage><pages>1072-1083</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T&gt; MIC ) and 100% (100% f T&gt; MIC ) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. Results. We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48–73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14–24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T&gt; MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P=.009). Positive clinical outcome was associated with increasing 50% f T&gt;MIC and 100% f T&gt; MIC ratios (OR, 1.02 and 1.56, respectively; P&lt;.03), with significant interaction with sickness severity status. Conclusions. Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.</abstract><cop>United States</cop><pub>OXFORD UNIVERSITY PRESS</pub><pmid>24429437</pmid><doi>10.1093/cid/ciu027</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2014-04, Vol.58 (8), p.1072-1083
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_1701481301
source Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Aged
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacokinetics
Antibiotics
ARTICLES AND COMMENTARIES
Bacterial Infections - drug therapy
beta-Lactams - administration & dosage
beta-Lactams - pharmacokinetics
Blood Chemical Analysis
Critical care
Critical Illness
Female
Health care industry
Health outcomes
Hospitals
Humans
Infections
Intensive Care Units
International Cooperation
Male
Microbial Sensitivity Tests
Middle Aged
Models, Statistical
Pathogens
Pharmacokinetics
Prospective Studies
Treatment Outcome
University hospitals
title DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T20%3A03%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DALI:%20Defining%20Antibiotic%20Levels%20in%20Intensive%20Care%20Unit%20Patients:%20Are%20Current%20%CE%B2-Lactam%20Antibiotic%20Doses%20Sufficient%20for%20Critically%20Ill%20Patients?&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Roberts,%20Jason%20A.&rft.aucorp=DALI%20Studya&rft.date=2014-04-15&rft.volume=58&rft.issue=8&rft.spage=1072&rft.epage=1083&rft.pages=1072-1083&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciu027&rft_dat=%3Cjstor_proqu%3E24031748%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1701481301&rft_id=info:pmid/24429437&rft_jstor_id=24031748&rfr_iscdi=true